Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours

BACKGROUND: Treatment options for patients with metastatic gastroenteropancreatic neuroendocrine tumours (GEP NETs) are still limited. We investigated the antitumour activity and safety profile of pazopanib – a multitarget drug with anti-angiogenic activity in patients with metastatic GEP NETs. METH...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Ahn, H K, Choi, J Y, Kim, K-M, Kim, H, Choi, S-H, Park, S H, Park, J O, Lim, H Y, Kang, W K, Lee, J, Park, Y S
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2013
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3776983/
https://ncbi.nlm.nih.gov/pubmed/23989950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.470
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados